Progenics Pharmaceuticals Inc (PGNX.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|57||2010||Independent Chairman of the Board|
|60||2011||Chief Executive Officer, Director|
|48||2015||Chief Financial Officer|
|62||2004||Senior Vice President - Manufacturing|
|58||2013||Senior Vice President - Operations and Portfolio Management|
- BRIEF-Progenics Pharmaceuticals says initiation of Phase 1 clinical trial for metastatic prostate cancer treatment
- BRIEF-Progenics Pharma enters controlled equity offering sales agreement with Cantor Fitzgerald
- BRIEF-Progenics Pharmaceuticals files for mixed shelf of up to $250 mln - SEC filing
- BRIEF-Progenics announces $50 million RELISTOR royalty-backed financing
- BRIEF-Valeant and Progenics announce the U.S. commercial launch of FDA-approved Relistor tablets